MSH|^~\&|LAB|ARH|||201911181126||ORU^R01|4106815|D|2.3|||AL|NE
PID|1||AB00008250|AB8149|LABTEST^HFE3^|||M||||||||||AB000500/19|
OBR|1|35233^LAB|00027068^1811:C00001R^LAB^181119:C1^35233|220.5080^HFE CD^Hemochromatosis-Conf Diagnosis^^^XXX-1182||201911180908|201911180909|||||||201911180909||||||||||LAB|I||||
OBR|2|35233^LAB|00027068^1811:C00001R^LAB^181119:C1^35233|520.4200^IRON^Iron Studies Profile^^^50190-8||201911180908|201911180909|||||||201911180909||||||||||LAB|F||||
OBX|1|ST|520.4300^FE^Iron^^14798-3^14798-3|1|25^^Y|umol/L|9-30|N||A^S|F|||201911181126
OBX|2|ST|520.4500^TIBC^Total Iron Binding Capacity^^14800-7^14800-7|1|29^^Y|umol/L|45-70|L||A^S|F|||201911181126
OBX|3|ST|520.4600^TRFSAT^Transferrin Saturation^^6796-7^14801-5|1|0.86^^Y||0.15-0.55|H||A^S|F|||201911181126
NTE|1||Markedly elevated transferrin saturation.  Follow up and
NTE|2||management as per BCMA/MSP Iron Overload protocol.